Risk for chronic kidney disease increases with obesity: Health Survey for England 2010

Helen L MacLaughlin1,2,*, Wendy L Hall2, Thomas AB Sanders2 and Iain C Macdougall1
1Department of Nutrition and Dietetics, King’s College Hospital, Denmark Hill, London SE5 9RS, UK: 2Diabetes and Nutritional Sciences Division, School of Medicine, King’s College London, London, UK

Submitted 21 October 2014: Final revision received 3 January 2015: Accepted 30 January 2015: First published online 6 March 2015

Abstract
Objective: Studies of the relationship between obesity and chronic kidney disease (CKD) in nationally representative population samples are limited. Our study aimed to determine if overweight and obesity were independently associated with the risk for CKD in the 2010 Health Survey for England (HSE).
Design: The HSE is an annually conducted cross-sectional study. In 2010 serum creatinine was included to determine the incidence of CKD in the population. CKD was defined as estimated glomerular filtration rate (eGFR) < 60 ml/min per 1·73 m² using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Multivariable logistic regression models were developed to calculate odds ratios and 95% confidence intervals for CKD risk by BMI (reference category: BMI = 18·5–24·9 kg/m²) and adjusted for age, gender, ethnicity, smoking, diabetes and hypertension.
Subjects: Adults (n = 3463) with calculable eGFR and BMI were included.
Results: The prevalence of CKD was 5·9%. The risk of CKD was over 2·5 times higher in obese participants compared with normal-weight participants in the fully adjusted model (BMI = 30·0–39·9 kg/m²: adjusted OR = 2·78 (95% CI 1·75, 4·43); BMI ≥ 40·0 kg/m²: adjusted OR = 2·68 (95% CI 1·05, 6·85)).
Conclusions: Obesity is associated with an increased risk of CKD in a national sample of the UK population, even after adjustment for known CKD risk factors, which may have implications for CKD screening and future national health service planning and delivery.

Studies examining the association between obesity and chronic kidney disease (CKD) have largely been conducted in local or regional, rather than national, population samples. Obesity has been identified as an independent risk factor for CKD and progression to kidney failure1–4, even after adjustment for hypertension and diabetes5–9. However, national population studies are lacking and this relationship has not been fully investigated in the UK, with limited studies suggesting a small increase in the risk of CKD with increasing BMI10,11.

The Health Survey for England (HSE) is an annual survey of a randomly selected, general population sample of adults and children in households across England, which may include both healthy individuals and those with acute and chronic illnesses12. In 2010, the HSE data set included serum creatinine (from which estimated glomerular filtration rate (eGFR) can be calculated) to assist in determining the prevalence of CKD in the population13, and this also provided the opportunity to examine the relationship between BMI and CKD in this nationally representative sample of the English population.

The present study sought to determine if overweight and obesity were independently associated with the risk for CKD (eGFR < 60 ml/min per 1·73 m²) in the 2010 HSE population sample of adults living in the UK.

Methods

Study population and setting
The HSE is an annual cross-sectional survey of households in England, which are randomly selected by postcode12. The anonymised data set is publicly available for the purposes of research and education14, thus ethical approval to use the HSE data set was not required. The HSE data set includes demographics, determinants of socio-economic status, self-reported dietary information, medications, co-morbidities, mental health measures,
anthropometric measures, and pre-specified analyses of blood, saliva and urine samples.

**Main outcome and measures**

The primary outcome was the risk of concomitant CKD as BMI increases in the HSE 2010 population with both BMI and a single serum creatinine measure recorded. Kidney function was defined as eGFR in ml/min per 1.73 m² calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula using serum creatinine, age, gender and ethnicity variables, including adjustment factors of ×1.212 if black race and ×0.742 if female(15). Kidney function was subsequently categorised using the Kidney Disease Outcomes Quality Initiative (KDOQI) stages of CKD(16). CKD was classified as CKD stage 3 or above, with an eGFR of <60 ml/min per 1.73 m².

Serum creatinine was measured in a single laboratory using the enzymatic Creatinine Plus (Roche) method on a Modular P analyser (Roche) for all study samples. BMI was calculated as [weight (kg)/[height (m)]² from height and weight measured by the study nurse, and categorised into underweight, normal range, overweight and obese classifications according to the WHO criteria(17). Participants aged ≥18 years with both a single serum creatinine value and calculated BMI of 15.0–60.0 kg/m² were included in the present study. BMI outside this range was deemed to be either incorrect or not representative of population norms and was therefore excluded. Baseline characteristics in the study population, including age, gender, ethnicity, eGFR, diabetes, hypertension and smoking status, were reported.

Diabetes and hypertension status data were collected routinely as part of the data set. Diabetes was classified as a self-reported previous diagnosis of diabetes; hypertension was classified as already receiving treatment (drug, dietary or lifestyle) for hypertension or with a recorded blood pressure of >140/90 mmHg measured by the study nurse(12). Smoking status was defined as never smoked (reference category), ex-smoker and current smoker.

**Statistical analyses**

Statistical analyses were completed using the statistical software package IBM SPSS Statistics version 19. Descriptive statistics were expressed as mean and standard deviation or as median and interquartile range for parametric and non-parametric continuous variables, respectively. Categorical variables were expressed as percentages. Baseline comparisons between continuous variables were performed using Student’s t test or the Mann–Whitney U test for parametric and non-parametric variables, respectively, and using Pearson’s χ² test for categorical variables. Normality of the data sets was established using visual assessment of histograms representing a normal curve and non-parametric continuous variables were converted into categorical variables.

Study participants were split into two groups according to eGFR. The CKD group was defined as eGFR < 60 ml/min per 1.73 m² and the non-CKD group as eGFR ≥ 60 ml/min per 1.73 m². Baseline characteristics of the groups were compared for age, gender, ethnicity, diabetes, hypertension and BMI. Participants in both groups were classified by WHO BMI criteria as underweight (<18.5 kg/m²), normal range (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), obese classes I and II (30.0–39.9 kg/m²) and obese class III (≥40.0 kg/m²). The distribution across BMI categories in the CKD group and the non-CKD group were compared using Pearson’s χ² test.

To evaluate the relationship between CKD and obesity in the study population, multivariable logistic regression models were developed to calculate odds ratios and 95 % confidence intervals. The BMI reference category was 18.5–24.9 kg/m². The unadjusted model (model 1) was built upon sequentially to include the predetermined potential confounders of age, gender and ethnicity (model 2), plus effect modifiers of smoking status, diabetes and hypertension (model 3). These analyses were repeated with CKD status classified using eGFR calculated with the four-variable Modification of Diet in Renal Disease (MDRD) study equation, using serum creatinine, age, gender and ethnicity variables, including adjustment factors of ×1.210 if black race and ×0.742 if female(18,19), to enable comparison with previous studies.

**Results**

The HSE 2010 included 8196 participants, of whom 4733 were excluded due to missing serum creatinine, height, weight, ethnicity, gender, hypertension or diabetes status information; resulting in a study sample population of 3463 adults (42.3 % of the survey population) with a valid BMI and calculable eGFR (Fig. 1). There were no significant differences in mean age or BMI, gender, ethnicity or prevalence of diabetes or hypertension between the excluded and included participants. The characteristics of the HSE study population and the CKD and non-CKD groups are described in Table 1. Two hundred and four (5.9 %) participants had an eGFR <60 ml/min per 1.73 m² and were classified as having CKD according to the study criteria. The CKD group was older, with a greater prevalence of diabetes and hypertension and had a higher mean BMI (all P<0.001) than those without CKD. The non-CKD group had greater representation from Black, Asian and other ethnic groups compared with the CKD group (P=0.03).

Over 65 % of the HSE 2010 study population was overweight or obese. The distribution of BMI for the entire study population, and for the CKD and non-CKD groups, is displayed in Table 2. The distribution of BMI differed between the CKD and non-CKD groups (χ²=30.85, df=4; P<0.001). There were more normal-weight and
overweight participants in the non-CKD group, compared with the CKD group, and the CKD group had a greater percentage of obese patients than the non-CKD group.

The unadjusted and adjusted odds ratios and 95% confidence intervals for the risk of CKD with increasing BMI are displayed in Table 3. The risk of CKD increased as BMI increased in the HSE 2010 population. In the unadjusted model (model 1), the risk of CKD was almost three times higher in those with a BMI of 30–39.9 kg/m² than in those with normal BMI. After adjustment for age, gender and ethnicity (model 2), the risk was attenuated but remained significant for the overweight group, while the risk increased with BMI ≥30.0 kg/m². With further adjustment for smoking, diabetes and hypertension (model 3), the risk of CKD was mitigated slightly, but remained over 2.5 times higher in those with BMI ≥30.0 kg/m², compared with those of normal weight. The risk for CKD in the overweight group was fully attenuated by adjusting for diabetes, hypertension and smoking status.

### Table 1 Characteristics of the Health Survey for England (HSE) 2010 study population as a whole and grouped by CKD-EPI equation-defined CKD status†

| Characteristic | HSE whole study population (n 3436) | Non-CKD group§ (n 3259) | CKD group¶ (n 204) | P
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Mean 51.1 sd 16.7</td>
<td>49.7 16.0</td>
<td>73.0 11.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Gender (% male)</td>
<td>44.2</td>
<td>44.3 44.1</td>
<td>0.96</td>
<td></td>
</tr>
<tr>
<td>Ethnicity (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>92.8</td>
<td>92.5 98.5</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>1.9</td>
<td>2.0 0.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>3.3</td>
<td>3.5 1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>2.0</td>
<td>2.0 0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>6.0</td>
<td>5.3 16.7</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>24.8</td>
<td>22.7 57.4</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>CKD-EPI eGFR (ml/min per 1.73 m²)</td>
<td>Mean 93.0 sd 19.3</td>
<td>95.8 16.3</td>
<td>49.4 9.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>Mean 27.6 sd 5.2</td>
<td>27.5 29.3</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.

†Data are presented as mean and standard deviation or as percentage prevalence.

‡eGFR ≥60 ml/min per 1.73 m².

§eGFR <60 ml/min per 1.73 m².

¶Comparison between non-CKD group and CKD group with unpaired Student t test.

### Table 2 Distribution across BMI categories of the Health Survey for England (HSE) 2010 study population as a whole and grouped by CKD-EPI equation-defined CKD status†

<table>
<thead>
<tr>
<th>BMI category (kg/m²)</th>
<th>HSE whole study population (n 3463)</th>
<th>Non-CKD group§ (n 3259)</th>
<th>CKD group¶ (n 204)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;18.5</td>
<td>29 0.8</td>
<td>0.8 1.0</td>
<td></td>
</tr>
<tr>
<td>18.5–24.9</td>
<td>1114 32.2</td>
<td>33.1 18.1</td>
<td></td>
</tr>
<tr>
<td>25.0–29.9</td>
<td>1380 39.9</td>
<td>40.0 38.2</td>
<td></td>
</tr>
<tr>
<td>30.0–39.9</td>
<td>852 24.6</td>
<td>23.7 38.7</td>
<td></td>
</tr>
<tr>
<td>≥40.0</td>
<td>88 2.5</td>
<td>2.5 3.9</td>
<td></td>
</tr>
</tbody>
</table>

χ² = 30.85, df = 4; P < 0.001

CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.

†Among those with a valid BMI and eGFR calculable with the CKD-EPI equation.

Data are presented as number and percentage or as percentage.

§eGFR ≥60 ml/min per 1.73 m².

lieGFR <60 ml/min per 1.73 m².
The prevalence of MDRD eGFR-decalified CKD in the study population was 7·6 % (n 254) compared with 5·9 % using CKD-EPI eGFR. There was a lower prevalence of CKD in obese study participants using MDRD eGFR than with CKD-EPI eGFR (38·1 % v. 42·6 %).

**Discussion**

Obesity, but not overweight, is associated with a significantly increased risk of CKD in a large, randomly selected, nationally representative, population sample in England. This is the first evidence to suggest that obesity is a substantial risk factor for CKD in a UK-based population, supporting the findings from previous studies in local and regional populations in Europe, Japan and North America(27,9). The higher risk associated with obesity in the present study, compared with previous studies in local UK populations(10,11), may reflect sampling biases in local v. national population data sets or differences in population samples (health practitioner-derived v. households randomly selected by postcode).

The strengths of the present study include the use of a nationally representative data set with uniform data collection, predefined terms and standardised methods of data input. The analyses were corrected for known potential confounding variables including age, gender and ethnicity, as well as smoking status, diabetes and hypertension. The cross-sectional design of the study has several limitations. First, by design, the study cannot determine causality or monitor the development of CKD over time. Second, while the HSE was carried out in people’s homes and they were apparently well at the time of the survey, it is not possible to determine whether the single creatinine measure obtained was representative of usual kidney function for all participants. The serum creatinine value used in the HSE was from a single measurement only, so the full definition of CKD, with a chronicity of at least 3 months, was not met in the present study; or in any other population-based study of the relationship between obesity and CKD. Furthermore, there may be other unconsidered (and therefore unaccounted for) variables which may affect the relationship examined.

The prevalence of CKD (eGFR <60 ml/min per 1·73 m²) in the present study population was just under 6 % using the CKD-EPI equation, which concurs with the 5 % prevalence in the HUNT II study in Norway(9). In cross-sectional studies of community-based samples, the fully adjusted risk for CKD (MDRD eGFR <60 ml/min per 1·73 m²) with obesity increased by 57 % when adjusted for

---

**Table 3** Logistic regression models for risk of concomitant CKD (CKD-EPI equation-defined eGFR < 60 ml/min per 1·73 m²) by BMI in the Health Survey for England (HSE) 2010 study population (n 3463)

<table>
<thead>
<tr>
<th>BMI category (kg/m²)</th>
<th>Model 1</th>
<th></th>
<th>Model 2</th>
<th></th>
<th>Model 3</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β OR 95 % CI</td>
<td></td>
<td>β OR 95 % CI</td>
<td></td>
<td>β OR 95 % CI</td>
<td></td>
</tr>
<tr>
<td>&lt;18·5</td>
<td>2·16 0·50, 9·43</td>
<td></td>
<td>2·28 0·30, 17·16</td>
<td></td>
<td>2·08 0·27, 15·74</td>
<td></td>
</tr>
<tr>
<td>18·5–24·9</td>
<td></td>
<td>1·00</td>
<td></td>
<td>1·00</td>
<td></td>
<td>1·00</td>
</tr>
<tr>
<td>25·0–29·9</td>
<td>1·75 1·17, 2·61</td>
<td></td>
<td>1·57 1·01, 2·44</td>
<td></td>
<td>1·48 0·94, 2·31</td>
<td></td>
</tr>
<tr>
<td>30·0–39·9</td>
<td>2·90 2·00, 4·46</td>
<td></td>
<td>3·14 2·00, 4·92</td>
<td></td>
<td>2·78 1·75, 4·43</td>
<td></td>
</tr>
<tr>
<td>≥40·0</td>
<td>2·92 1·31, 6·47</td>
<td></td>
<td>3·42 1·37, 8·56</td>
<td></td>
<td>2·68 1·05, 6·85</td>
<td></td>
</tr>
</tbody>
</table>

**Table 4** Logistic regression models for risk of concomitant CKD (MDRD equation-defined eGFR < 60 ml/min per 1·73 m²) by BMI in the Health Survey for England (HSE) 2010 study population (n 3463)

<table>
<thead>
<tr>
<th>BMI category (kg/m²)</th>
<th>Model 1</th>
<th></th>
<th>Model 2</th>
<th></th>
<th>Model 3</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β OR 95 % CI</td>
<td></td>
<td>β OR 95 % CI</td>
<td></td>
<td>β OR 95 % CI</td>
<td></td>
</tr>
<tr>
<td>&lt;18·5</td>
<td>1·53 0·35, 6·62</td>
<td></td>
<td>1·81 0·34, 9·74</td>
<td></td>
<td>1·73 0·32, 9·47</td>
<td></td>
</tr>
<tr>
<td>18·5–24·9</td>
<td></td>
<td>1·00</td>
<td></td>
<td>1·00</td>
<td></td>
<td>1·00</td>
</tr>
<tr>
<td>25·0–29·9</td>
<td>1·70 1·20, 2·40</td>
<td></td>
<td>1·41 0·98, 2·03</td>
<td></td>
<td>1·37 0·95, 1·99</td>
<td></td>
</tr>
<tr>
<td>30·0–39·9</td>
<td>2·42 1·69, 3·43</td>
<td></td>
<td>2·14 1·46, 3·12</td>
<td></td>
<td>2·02 1·37, 2·97</td>
<td></td>
</tr>
<tr>
<td>≥40·0</td>
<td>2·35 1·12, 4·96</td>
<td></td>
<td>2·29 1·03, 5·10</td>
<td></td>
<td>2·01 0·89, 4·54</td>
<td></td>
</tr>
</tbody>
</table>

CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate.

Model 1, unadjusted; model 2, adjusted for age, gender and ethnicity; model 3, adjusted for age, gender, ethnicity, smoking, diabetes and hypertension.

*P <0·05, **P <0·01, ***P <0·001.
Chronic kidney disease risk increases with obesity

age and gender only in the HUNT II study⁵⁹, and the risk for CKD with overweight and obesity combined doubled in a Japanese community population⁷⁷. In our study the risk for CKD was similar using the MDRD study equation, yet the fully adjusted risk for CKD, using the CKD-EPI equation, was over 2.5 times as high for obese participants compared with normal-weight controls. Using the CKD-EPI equation reduced the percentage of patients classified with CKD compared with the MDRD study equation in the present study, as expected, because the MDRD study equation systematically underestimates GFR at higher levels of GFR¹⁵, leading to false classification of CKD. The CKD-EPI equation was developed and validated across a wider range of GFR, including those with normal kidney function, to improve the precision of the estimation of GFR at higher levels of kidney function¹⁵. Although the overall percentage of participants classified with CKD was lower when using the CKD-EPI equation than the MDRD study equation, there was a greater proportion of obese participants in the CKD-EPI-classified CKD group than in the MDRD-defined CKD group. The CKD-EPI equation has good agreement with measured GFR in obese patients with CKD²⁰, therefore lowering the risk of misclassification, which may explain, at least partially, why the risk of CKD with obesity is greater using CKD-EPI-defined eGFR.

In the Hypertension Detection and Follow Up Program population, obese patients with hypertension, a known risk factor for CKD, had a fully adjusted risk of CKD 25% higher than normal-weight hypertensive patients²³, indicating that the added risk of obesity for CKD in populations with other identified CKD risk factors may be lower than in studies of mixed or apparently healthy community populations. The independent risk of obesity may appear higher in the ‘healthy’ obese populations, not because the absolute risk is any higher, but because the difference in risk between the groups is reduced. In ‘healthy’ populations, the comparator group lacks other contributing risk factors for CKD that are present in the populations with existing CVD and hypertension.

The evidence presented in the current study demonstrates a concomitant relationship between obesity and CKD in a nationally representative, randomly selected sample from the English population. Given the epidemic rise in population obesity rates in the UK¹⁴, it is recommended that obesity be considered as a risk factor for CKD in guidelines for detection of CKD and that future national health service delivery planning considers interventions to prevent and retard the development and progression of CKD.

Acknowledgements

Acknowledgements: HSE 2010 data were made available by the Information Centre for Health and Social Care (copyright 2012, reused with the permission of the UK Data Service). Financial support: This work was supported by a doctoral research fellowship funded by King’s College Hospital NHS Foundation Trust. King’s College Hospital NHS Foundation Trust had no role in the design, analysis or writing of this article. Conflict of interest: None. Authorship: All authors provided substantial contributions to study conception, design and interpretation of data. H.L.M. analysed the data and drafted the initial manuscript. All authors were involved in revising the manuscript critically for important intellectual content and approved the final version to be published. Ethics of human subject participation: Ethical approval to use the HSE data set was not required.

References

Health Surveys Unit of the National Centre for Social Research (NatCen) and the Department of Epidemiology and Public Health at the University College London (UCL) Medical School; available at http://www.hscic.gov.uk/pubs/hse10report


